PLRX — Pliant Therapeutics Share Price
0.000.00%
Last trade - 00:00- $89.62m
- -$235.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.29 | ||
| Price to Tang. Book | 0.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.78% | ||
| Return on Equity | -54.09% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 41.82 | 7.57 | 9.69 | 1.58 | n/a | 3.5 | 2 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Directors
- Bernard Coulie PRE (55)
- Keith Cummings CFO (44)
- Barbara Howes CHO (56)
- Mike Ouimette GCN (48)
- Hans Hull OTH (46)
- Eric Lefebvre OTH (57)
- Hoyoung Huh LED (51)
- Suzanne Bruhn IND (57)
- Gayle Crowell IND (70)
- John Curnutte IND (69)
- Neil Exter IND (62)
- Charles Homcy IND (72)
- David Pyott IND (68)
- Smital Shah IND (45)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 8th, 2015
- Public Since
- June 3rd, 2020
- No. of Shareholders
- 36
- No. of Employees
- 171
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 61,386,278
- Address
- 331 Oyster Point Boulevard, SOUTH SAN FRANCISCO, 94080
- Web
- https://pliantrx.com/
- Phone
- +1 6504816770
- Contact
- Christopher Keenan
- Auditors
- Deloitte & Touche LLP
Upcoming Events for PLRX
Pliant Therapeutics Inc Annual Shareholders Meeting
Pliant Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Pliant Therapeutics Inc Earnings Release
Similar to PLRX
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Pliant Therapeutics share price?
As of Today at 22:40 UTC, shares in Pliant Therapeutics are trading at $1.46. This share price information is delayed by 15 minutes.
How has the Pliant Therapeutics share price performed this year?
Shares in Pliant Therapeutics last closed at $1.46 and the price had moved by -87.71% over the past 365 days. In terms of relative price strength the Pliant Therapeutics share price has underperformed the S&P500 Index by -88.66% over the past year.
What are the analyst and broker recommendations for Pliant Therapeutics?
The overall consensus recommendation for Pliant Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pliant Therapeutics dividend yield?
Pliant Therapeutics does not currently pay a dividend.
Does Pliant Therapeutics pay a dividend?
Pliant Therapeutics does not currently pay a dividend.
When does Pliant Therapeutics next pay dividends?
Pliant Therapeutics does not currently pay a dividend.
How do I buy Pliant Therapeutics shares?
To buy shares in Pliant Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pliant Therapeutics?
As of the previous close price of $1.46, shares in Pliant Therapeutics had a market capitalisation of $89.62m.
Where are Pliant Therapeutics shares listed?
Here are the trading details for Pliant Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PLRX
What kind of share is Pliant Therapeutics?
Based on an overall assessment of its quality, value and momentum Pliant Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pliant Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Pliant Therapeutics is $4.79. That is 228.08% above the last closing price of $1.46.
Analysts covering Pliant Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.30 for the next financial year.
Find out moreWhat is the trend in the Pliant Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pliant Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -89.12%.
As of the last closing price of $1.46, shares in Pliant Therapeutics were trading -85.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pliant Therapeutics PE Ratio?
The Pliant Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pliant Therapeutics?
Pliant Therapeutics' management team is headed by:
- Bernard Coulie - PRE
- Keith Cummings - CFO
- Barbara Howes - CHO
- Mike Ouimette - GCN
- Hans Hull - OTH
- Eric Lefebvre - OTH
- Hoyoung Huh - LED
- Suzanne Bruhn - IND
- Gayle Crowell - IND
- John Curnutte - IND
- Neil Exter - IND
- Charles Homcy - IND
- David Pyott - IND
- Smital Shah - IND